You are here

Myocardial Repair by Targeted Stem Cells

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HL079720-02A2
Agency Tracking Number: HL079720
Amount: $1,735,800.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Timeline
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PANORAMA RESEARCH, INC. 1230 BORDEAUX DRIVE
SUNNYVALE, CA 94089
United States
DUNS: 556962439
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JAMES LARRICK
 (415) 264-6311
 OSP@PANO.COM
Business Contact
Phone: (408) 757-5201
Email: ops@pano.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): There is an urgent need for improved therapies for acute and chronic myocardial ischemia. Bone marrow-derived stem cells (SC) injected into acutely injured as well as chronically ischemic myocardium improve left ventric
ular function. However, a major limitation of direct infusion or injection of SC is the targeting and retention of these cells at the site of myocardial injury. To address these problems, we have developed an improved, proprietary approach using bispecific
antibody (BiMab)-targeted SC. This approach is less invasive, more specific and more efficacious. In phase I we used a xenogeneic rodent model of myocardial infarction (MI) to demonstrate that CD34+ SC derived from human peripheral blood can be antibody-t
argeted to injured myocardium when injected intravenously. In these studies an anti-CD45 antibody recognizing the CD34+ enriched SCs was chemically conjugated to an antibody recognizing myosin light chain (MLC) exposed in injured cardiac tissue. Starting t
wo weeks post-MI and extending for at least 3 months, individuals receiving BiMab-armed SC had significantly improved myocardial function vs. those receiving unarmed SC. These exciting results provide proof-of-concept for antibody-targeted SC to enhance my
ocardial repair. In Phase II, to further develop and improve this technology with the ultimate aim of filing an IND, we will identify and characterize human antibodies recognizing CD45 and MLC. The recombinant human monoclonal antibodies (Mabs) will be lin
ked to create a BiMab, CorTarga, which will be evaluated using a preclinical rat model of myocardial infarction. Efficacy will be improved by optimizing cell types and numbers, timing of and strategies for administration of CorTarga. Finally, pre-clinica
l pharmacology and toxicology studies will be initiated. Successful outcome of this work will demonstrate a general method to improve the use of stem cell therapies for severe cardiac disease as well as many other indications in cell-based regenerative med
icine. PUBLIC HEALTH RELEVANCE: Myocardial repair by targeted stem cells Major problems of cell targeting and retention limit the efficacy of stem cell therapy for myocardial injury. Bispecific antibodies recognizing an injury specific target and an antige
n on the stem cells provides a novel means to greatly improve the efficiency of cell-based regenerative therapies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government